# Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

> **NCT02503709** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 29 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Unresectable Solid Neoplasm

## Interventions

- **DRUG:** CDK Inhibitor AT7519
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Onalespib
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02503709
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-30
- **Primary completion:** 2020-08-15
- **Final completion:** 2020-10-09
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02503709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02503709, "Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02503709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*